In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 Euro...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Guillermo Quindós, Katherine Miranda-Cadena, Rosario San-Millán, Katyna Borroto-Esoda, Emilia Cantón, María José Linares-Sicilia, Axel Hamprecht, Isabel Montesinos, Anna Maria Tortorano, Anna Prigitano, Matxalen Vidal-García, Cristina Marcos-Arias, Andrea Guridi, Ferran Sanchez-Reus, Jesús Machuca-Bárcena, Manuel Antonio Rodríguez-Iglesias, Estrella Martín-Mazuelos, Carmen Castro-Méndez, Leyre López-Soria, Alba Ruiz-Gaitán, Marcelo Fernandez-Rivero, Damaris Lorenzo, Javier Capilla, Antonio Rezusta, Javier Pemán, Josep Guarro, Joana Pereira, Célia Pais, Orazio Romeo, Guillermo Ezpeleta, Nerea Jauregizar, David Angulo, Elena Eraso
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2022-05-01
Serie:	Frontiers in Cellular and Infection Microbiology
Soggetti:	antifungal testing antifungal resistance Candida ibrexafungerp SCY-078 EUCAST
Accesso online:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.906563/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!